Osteopetrosis in the ia/ia rat is known to be the result of reduced bone resorption due to abnormal osteoclasts. Studies in this mutant have shown that mononuclear cells from normal littermates could cure the skeletal sclerosis and result in the formation of normal osteoclasts when transplanted into ia/ia rats. This investigation was pursued in an attempt to determine the cellular source of this cure by transplanting various populations of cells from 21 -day-old normal rats to unrelated newborn ia/ia recipients. The effects of treatment were evaluated radiographically and by measuring the size of the tibial marrow cavity. The cellular suspensions that were effective in curing the disease were the Ficoll-Hypaque isolate of spleen, bone marrow, and newborn livers. The Ficoll-Hypaque isolates of lymph node, thymus, and blood, and the adherent pool of peritoneal cells and splenic cells did not produce a cure in the ia/ia recipients. These results suggest that the cellular source of the cure is a stem cell. This conclusion is further substantiated by the finding that Thy 1.1 antigen (a stem cell marker in the rat) is expressed on a majority of the cells from the donor sources that affected a cure.

Keywords:
Bone resorption, Osteoclast, Osteopetrosis, Skeletal sclerosis, Stem cell, Transplantation
This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.